Back

Revivifying research on relaxin receptor-targeted therapy for cardiovascular diseases

Cardiovascular Research

17 April 2025
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY HEART FAILURE Chronic Heart Failure HYPERTENSION BASIC SCIENCE

Contributors

Xiao-Jun Du
Xiao-Jun Du

Author

You may be interested in
thumbnail
Congress Presentation
The anti-arrhythmic properties of relaxin in heart failure with preserved ejection fraction
21 May 2023
thumbnail
Congress Presentation
Paracrine cardioprotective signaling by red blood cells through hypoxia-mediated activation of soluble guanylate cyclase and release of cyclic guanosine monophosphate
26 August 2023
thumbnail
Congress Session
New frontiers in heart failure therapies
19 May 2025
thumbnail
Congress Presentation
KAND567, the first selective small molecule CX3CR1 antagonist in clinical development, mediates anti-inflammatory cardioprotective effects in rodent models of atherosclerosis and myocardial infarction
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources